Table 1.

Clinical and genomic characteristics of rectal GIST patients depending on when imatinib (IM) became available.

	Pre-IM era	IM era	p-value
Total number	17	30
Follow-up (yrs)
Median	4.5	3.7	0.32
Range	0.7 – 16.4	0.1 – 13.0
Sex
Male	10	22	0.34
Female	7	8
Age at resection (yrs)
Median	58	57	0.37
Range	43 – 78	23 – 82
Tumor size (cm)*
Median	5	4	0.03
Range	0.6 – 21.0	0.8 – 9.5
Distance to AV (cm)
Median	4	4	0.3
Range	1.0 – 8.0	0.0 – 6.0
Miettinen high-risk**
Yes	15	19	0.16
No	2	9
Presentation
Symptoms	13	16	0.11
Exam or endoscopy	3	14
Mutation
KIT exon 9	1 (5.9%)	0 (0.0%)
KIT exon 11 del	8 (47.1%)	8 (26.7%)
KIT exon 11 pm	0 (0.0%)	4 (13.3%)	0.35
KIT exon 13	0 (0.0%)	1 (3.3%)
KIT exon 11 and 17	0 (0.0%)	1 (3.3%)
PDGFRα	0 (0.0%)	0 (0.0%)
Wild type	3 (17.6%)	5 (16.7%)
Not tested	5 (29.4%)	11 (36.7%)

^*For tumors receiving neoadjuvant imatinib, size was based on pretreatment imaging.

^**Some patients lacked necessary clinicopathologic data to determine Miettinen risk.

del=deletion, pm=point mutation